Condensed Consolidated Statements of Operations - USD ($) $ in Thousands		3 Months Ended		9 Months Ended
		Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2021	Dec. 31, 2020
Pfizer collaboration revenue		$ 25,172	$ 1,379	$ 79,853	$ 1,379
Total revenues		54,440	1,379	173,405	34,712
Collaboration expense to Pfizer		12,086	0	25,912	0
Research and development		25,726	30,453	82,886	115,160
Selling, general and administrative	[1]	72,125	49,243	192,118	103,387
Total operating costs and expenses		114,180	79,696	308,813	218,547
Loss from operations		(59,740)	(78,317)	(135,408)	(183,835)
Interest expense	[2]	3,479	2,609	10,478	6,908
Interest income		(70)	(32)	(248)	(178)
Foreign exchange gain		0	(5,891)	0	(16,178)
Loss before income taxes		(63,149)	(75,003)	(145,638)	(174,387)
Income tax expense (benefit)		296	(1,154)	1,058	(616)
Net loss		$ (63,445)	$ (73,849)	$ (146,696)	$ (173,771)
Net loss per common share - basic (in USD per share)		$ (0.68)	$ (0.82)	$ (1.59)	$ (1.94)
Net loss per common share - diluted (in USD per share)		$ (0.68)	$ (0.82)	$ (1.59)	$ (1.94)
Weighted average common shares outstanding - basic (in shares)		93,474,985	90,096,557	92,514,657	89,715,160
Weighted average common shares outstanding - diluted (in shares)		93,474,985	90,096,557	92,514,657	89,715,160
Product revenue, net
Revenues		$ 29,268	$ 0	$ 61,885	$ 0
Cost of revenue		4,243	0	7,897	0
Richter license and milestone revenue
Revenues		$ 0	$ 0	$ 31,667	$ 33,333

[1] Includes $1,337 and $3,784 of related party expense (inclusive of third-party pass-through costs) for the three and nine months ended December 31, 2021, respectively. Includes $1,671 and $3,076 of related party expense (inclusive of third-party pass-through costs) for the three and nine months ended December 31, 2020, respectively (see Note 5).

[2] Includes $2,871 and $8,660 of interest expense under the Sumitomo Dainippon Pharma Loan Agreement for the three and nine months ended December 31, 2021, respectively. Includes $2,569 and $6,868 of interest expense under the Sumitomo Dainippon Pharma Loan Agreement for the three and nine months ended December 31, 2020, respectively (see Note 5).